We are analyzing https://link.springer.com/article/10.1007/s10557-013-6459-8.

Title:
The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives | Cardiovascular Drugs and Therapy
Description:
Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral anti-hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), are effective in the treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors play important protective roles in the cardiovascular system. DPP-4 inhibitors act to decrease myocardial infarct size, stabilize the cardiac electrophysiological state during myocardial ischemia, reduce ischemia/reperfusion injury, and prevent left ventricular remodeling after myocardial infarction. Moreover, DPP-4 inhibitors can mobilize stem/progenitor cells to move to sites of cardiovascular injury, thus further promoting tissue repair. In addition, DPP-4 inhibitors not only improve myocardial metabolism but also regulate cardioactive peptides. DPP-4 inhibitors can also protect the vasculature through their anti-inflammatory and anti-atherosclerotic effects and through the ability of the inhibitors to promote vascular relaxation. Finally, the potential effects of DPP-4 inhibitors on blood pressure and lipid metabolism have also been investigated. However, some reports on the cardioprotective activities of DPP-4 inhibitors are controversial. Herein, we summarize the available data on cardiovascular protection by DPP-4 inhibitors that have emerged in recent years and discuss current position and future perspectives concerning the use of DPP-4 inhibitors in cardiovascular medicine.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, pubmed, cas, dipeptidyl, dpp, diabetes, peptidase, cardiovascular, inhibitors, inhibition, inhibitor, myocardial, type, patients, mice, peptide, effects, heart, cell, glucagonlike, sitagliptin, endothelial, cells, improves, metab, physiol, cardiovasc, pharmacol, function, protection, infarction, effect, rats, med, content, blood, disease, zhang, cardiol, dipeptidylpeptidase, stem, privacy, cookies, data, drugs, role, treatment, injury,

Topics {✒️}

yue-jin yang & yong-jian wu camp-response element-binding protein dp iv/cd26-knockout mice dipeptidyl peptidase-iv inhibitor month download article/chapter stromal-derived factor-1alpha increases sdf-1-driven homing yue-jin yang mobilize stem/progenitor cells oral anti-hyperglycemic agents yong-jian wu pacing-induced dilated cardiomyopathy overpacing-induced heart failure glucose-dependent insulinotropic polypeptide apolipoprotein e-deficient mice erk-dependent mmp-1 expression diabetic ob/ob mice amino]acetyl}-pyrrolidine-2-carbonitrile endothelial progenitor cells dipeptidyl peptidase-4 activity dipeptidyl-peptidase iv dipeptidyl peptidase iv reduce ischemia/reperfusion injury cd26/dpp-iv inhibition dipeptidyl peptidase-4 inhibitor dipeptidyl peptidase-4 inhibition dipeptidyl-peptidase 4 inhibition insulin resistance induced b-type natriuretic peptide article cardiovascular drugs de boer ra full article pdf dipeptidyl peptidase-4 inhibitors improves endothelial function progenitor cell trafficking acute myocardial infarction privacy choices/manage cookies improves myocardial function dpp-iv inhibitor arterial blood pressure peptide-1 improves proliferation cardiac electrophysiological state multiple oral doses cell stem cell alogliptin versus standard article wang peptide 1 receptor-dependent fadini gp zaruba mm stem cells dev

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives
         description:Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral anti-hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), are effective in the treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors play important protective roles in the cardiovascular system. DPP-4 inhibitors act to decrease myocardial infarct size, stabilize the cardiac electrophysiological state during myocardial ischemia, reduce ischemia/reperfusion injury, and prevent left ventricular remodeling after myocardial infarction. Moreover, DPP-4 inhibitors can mobilize stem/progenitor cells to move to sites of cardiovascular injury, thus further promoting tissue repair. In addition, DPP-4 inhibitors not only improve myocardial metabolism but also regulate cardioactive peptides. DPP-4 inhibitors can also protect the vasculature through their anti-inflammatory and anti-atherosclerotic effects and through the ability of the inhibitors to promote vascular relaxation. Finally, the potential effects of DPP-4 inhibitors on blood pressure and lipid metabolism have also been investigated. However, some reports on the cardioprotective activities of DPP-4 inhibitors are controversial. Herein, we summarize the available data on cardiovascular protection by DPP-4 inhibitors that have emerged in recent years and discuss current position and future perspectives concerning the use of DPP-4 inhibitors in cardiovascular medicine.
         datePublished:2013-05-07T00:00:00Z
         dateModified:2013-05-07T00:00:00Z
         pageStart:297
         pageEnd:307
         sameAs:https://doi.org/10.1007/s10557-013-6459-8
         keywords:
            Dipeptidyl peptidase-4 inhibitors
            Cardiovascular protection
            Myocardial infarction
            Atherosclerosis
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig3_HTML.gif
         isPartOf:
            name:Cardiovascular Drugs and Therapy
            issn:
               1573-7241
               0920-3206
            volumeNumber:27
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xi-Mei Wang
               affiliation:
                     name:Chinese Academy of Medical Sciences and Peking Union Medical College
                     address:
                        name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yue-Jin Yang
               affiliation:
                     name:Chinese Academy of Medical Sciences and Peking Union Medical College
                     address:
                        name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Yong-Jian Wu
               affiliation:
                     name:Chinese Academy of Medical Sciences and Peking Union Medical College
                     address:
                        name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives
      description:Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral anti-hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), are effective in the treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors play important protective roles in the cardiovascular system. DPP-4 inhibitors act to decrease myocardial infarct size, stabilize the cardiac electrophysiological state during myocardial ischemia, reduce ischemia/reperfusion injury, and prevent left ventricular remodeling after myocardial infarction. Moreover, DPP-4 inhibitors can mobilize stem/progenitor cells to move to sites of cardiovascular injury, thus further promoting tissue repair. In addition, DPP-4 inhibitors not only improve myocardial metabolism but also regulate cardioactive peptides. DPP-4 inhibitors can also protect the vasculature through their anti-inflammatory and anti-atherosclerotic effects and through the ability of the inhibitors to promote vascular relaxation. Finally, the potential effects of DPP-4 inhibitors on blood pressure and lipid metabolism have also been investigated. However, some reports on the cardioprotective activities of DPP-4 inhibitors are controversial. Herein, we summarize the available data on cardiovascular protection by DPP-4 inhibitors that have emerged in recent years and discuss current position and future perspectives concerning the use of DPP-4 inhibitors in cardiovascular medicine.
      datePublished:2013-05-07T00:00:00Z
      dateModified:2013-05-07T00:00:00Z
      pageStart:297
      pageEnd:307
      sameAs:https://doi.org/10.1007/s10557-013-6459-8
      keywords:
         Dipeptidyl peptidase-4 inhibitors
         Cardiovascular protection
         Myocardial infarction
         Atherosclerosis
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-013-6459-8/MediaObjects/10557_2013_6459_Fig3_HTML.gif
      isPartOf:
         name:Cardiovascular Drugs and Therapy
         issn:
            1573-7241
            0920-3206
         volumeNumber:27
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xi-Mei Wang
            affiliation:
                  name:Chinese Academy of Medical Sciences and Peking Union Medical College
                  address:
                     name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yue-Jin Yang
            affiliation:
                  name:Chinese Academy of Medical Sciences and Peking Union Medical College
                  address:
                     name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Yong-Jian Wu
            affiliation:
                  name:Chinese Academy of Medical Sciences and Peking Union Medical College
                  address:
                     name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cardiovascular Drugs and Therapy
      issn:
         1573-7241
         0920-3206
      volumeNumber:27
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Chinese Academy of Medical Sciences and Peking Union Medical College
      address:
         name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
         type:PostalAddress
      name:Chinese Academy of Medical Sciences and Peking Union Medical College
      address:
         name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
         type:PostalAddress
      name:Chinese Academy of Medical Sciences and Peking Union Medical College
      address:
         name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xi-Mei Wang
      affiliation:
            name:Chinese Academy of Medical Sciences and Peking Union Medical College
            address:
               name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
               type:PostalAddress
            type:Organization
      name:Yue-Jin Yang
      affiliation:
            name:Chinese Academy of Medical Sciences and Peking Union Medical College
            address:
               name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Yong-Jian Wu
      affiliation:
            name:Chinese Academy of Medical Sciences and Peking Union Medical College
            address:
               name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
      name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
      name:Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(244)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.91s.

LINK . SPRINGER . COM {}